Perceptual Abnormalities and Their Malleability in BDD
ConditionBody Dysmorphic Disorder
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-40
SponsorCentre for Addiction and Mental Health
About this trial
A core symptom of body dysmorphic disorder (BDD) is perceptual distortions for appearance, which contributes to poor insight and delusionality, limits engagement in treatment, and puts individuals at risk for relapse. Results from this study will provide a comprehensive mechanistic model of brain, behavioral, and emotional contributors to abnormal perceptual processing, as well as how malleable it is with visual modulation techniques. This will lay the groundwork for next-step translational perceptual retraining approaches.
Eligibility criteria
Qualifiers
males or females
ages 18-40
meet Diagnostic and Statistical Manual-5 (DSM-5) criteria for Body Dysmorphic Disorder
have a Body Dysmorphic Disorder version of the Yale-Brown Obsessive-Compulsive Disorder Scale (BDD-YBOCS) score of ≥20
Disqualifiers
concurrent major Axis I disorders including substance use disorders, aside from anxiety disorders or depressive disorders, as these comorbidities are very common and the sample would otherwise be non-representative; however BDD must be the primary diagnosis.
lifetime: bipolar disorder or psychotic disorder.
psychotropic medications, aside from a short half-life sedative/hypnotic for insomnia, or a short half-life benzodiazepine as needed for anxiety but not exceeding a frequency of 3 doses in one week and not to be taken on the days of the training or MRI scan
current cognitive-behavioral therapy
Trial design
Treatments tested in this trial
- attentional modulation
- perceptual modulation
- naturalistic viewing
Treatment groups
146 Participants
are divided into 3 treatment groupsSponsors and collaborators
Centre for Addiction and Mental Health
Lead sponsor
National Institute of Mental Health (NIMH)
Collaborator
University of Alabama at Birmingham
Collaborator
University of Toronto
Collaborator
Source ClinicalTrials.gov